Valacyclovir prophylaxis in herpes zoster ophthalmicus (HZO) showed reduced risk of recurrent keratitis and iritis, particularly during early treatment and observation periods.
Time-varying analysis indicates greatest potential benefit within the first 6 months of suppressive therapy.
Although statistical significance was not achieved, findings support the current recommendation of one-year valacyclovir prophylaxis to manage ocular complications of HZO.
Post hoc exploratory design highlights need for cautious interpretation and further validation.
